Not only can it be cured, but it can also be prevented? AstraZeneca Farxiga reduces risk of new diabetes by 32%

Read: Farxiga reduced the risk of new type 2 diabetes by nearly a third compared to placeboexploratory analysis of DAPA-HF, the AstraZeneca SGLTT2 inhibitor Farxiga (dapagliflozin), at the 80th American Diabetes Association (ADA) scientific meeting this month, showed that the drug showed signs of preventing type 2 diabetes: Farxiga reduced the risk of new type 2 diabetes by nearly a third compared to placeboFarxiga, an effective treatment for type 2 diabetes, was also approved in May for a new indication that is used in adult patients with reduced blood score reduction heart failure (HFrEF) to reduce the risk of cardiovascular death and heart failure hospitalization, regardless of whether they have type 2 diabetesThe new findings, which represent an emerging market for SGLT2 inhibitors, are believed to help drive sales of new farxiga usesThe data may also prompt endocrinologists to consider early use of these drugs in diabetes treatmentdiabetes prevention analysis has been pre-specified in the DAPA-HF study, but this new finding is only considered exploratoryDAPA-HF, a heart failure trial, recruited 4,774 hFrEF patients, about half of whom had no diabetes at the time of the study, and were evenly distributed to the Farxiga and placebo groupsOf the 1298 patients in the Farxiga group who did not have diabetes, 4.9% developed type 2 diabetes within 18 months, compared with 7.1% of the 1307 patients in the placebo group, which was equivalent to reducing the risk of new type 2 diabetes by 32% (p-0.019)lead researcher at DAPA-HF and a professor of medicine at Yale University School of Medicine, DrSilvio Inzucchi, said there were some limitations to the analysis, including a shorter follow-up time and that the study was not purely a diabetes prevention trialHowever, farxiga had little effect on HbA1c or weight in patients with out-of-the-line diabetes at baselineThis suggests that the inhibitory effect of SGLT2 may not be just preventing the development of diabetes, a problem that has been raised after other diabetes prevention studies of sugar-lowering drugsmetformin has long been a generic diabetes drug and is thought to have the most evidence to support its use in prevention, largely based on a 20-year trial called Diabetes Program Prevention Program, which found that metformin reduced the risk of diabetes in patients with impaired sugar tolerance by 31 percentInzucchi notes that the risk reduction found in DAPA-HF by 32% "suggests that in The HFrEF population, it may be possible to consider adjusting these guidelines to include the possibility of SGLT2 inhibitors as a baseline therapy, even before the use of metformin."askedwhether endocrine meth should reconsider metformin as the first drug for diabetes, Inzucchi said: "Is metformin more used outside the diabetes guidelines than SGLT2, especially in patients with cardiovascular disease? Obviously not, the use of metformin is largely based on a traditionMany patients need at least 2 drugs, so why not use SGLT2 inhibitors while using metformin? "
of course, this is a pleasant message for all SGLT2 inhibitor manufacturersIn addition to AstraZeneca, which includes Lilly and Briginger and Invokana, the drug companies have invested in huge clinical projects aimed at expanding the use of these drugs to heart and kidney diseaseAnd, as evidence of the widespread protective effects of SGLT2 inhibitors grows, sales forecasts for such drugs soarat this point, the mechanism behind the broad benefits of SGLT2 inhibitors is not entirely clear, although most agree that many different approaches may workJoris Silon, senior vice president of cardiovascular, kidney and metabolic atAstraZeneca, speculates that SGLT2 inhibitors promote the loss of salt and glucose in the urine, and that a range of physiological adaptations to the process may provide preventive benefitsJoris Silon also said AstraZeneca is unlikely to conduct any specific diabetes prevention studies on Farxiga and to seek diabetes preventionhowever, real-world evidence promises to add to this discoveryThe DAPA-CKD study, which tested Farxiga in patients with chronic kidney disease (CKD), also included an exploratory diabetes prevention analysisThe study was discontinued early in March this year because of its significant efficacyreducing the risk of end-stage kidney disease or death in all CDK patients is a huge victory, as was the goal of reducing hospitalization and mortality for heart failure in all patients in the DAPA-HF studyAs SGLT2 inhibitors show benefits in a growing number of patients, finding diabetes prevention signals will undoubtedly be the icing on the cake for such drugsreference source: Diabetes data signal emerges for Farxiga.